Skip to main content
SpringerLink
Log in

Is Pharmacotherapy for Benign Prostatic Hyperplasia an Alternative?

  • Conference paper
Benign Prostatic Hyperplasia

  • 95 Accesses

Abstract

Benign prostatic hyperplasia (BPH) is probably the commonest benign human neoplasm. Histologically identifiable hyperplastic changes in the prostate are present in approximately 50% of men at the age of 60 and in nearly 100% of men by 80 years [39]. Although the histological prevalence of a disease cannot be equated with its associated clinical picture, it has been reported that three-quarters of men over the age of 50 will suffer symptoms suggestive of BPH. Furthermore, it is estimated that the prevalence of significant BPH, defined as an enlargement of the prostate gland greater than 15ml/s in the presence of symptoms and/or a urinary flow rate under 15ml/s; and without evidence of malignancy, was 253/1000 in a sample of 705 men aged 40–79 registered with a group general practice in Scotland [27]. In the United States Glynn et al. [32] calculated the chance of a 40-year-old man subsequently requiring a prostatectomy as 29%.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abrams PH (1977) A double-blind trial of the effects of candicidin on patients with benign prostatic hypertrophy. Br J Urol 49:67–71

    Article  PubMed  CAS  Google Scholar 

  2. Abrams PH, Shah PJR, Stone AR, Choa RG (1981) Bladder outflow obstruction treated with phenoxybenzamine. Prog Clin Biol Res 78:269–275

    PubMed  CAS  Google Scholar 

  3. Abrams PH, Shah PJR, Stone AR, Choa RG (1982) Bladder outflow obstruction treated with phenoxybenzamine. Br J Urol 54:527–530

    Article  PubMed  CAS  Google Scholar 

  4. Abrams PH (1985) Detrusor instability and bladder outlet obstruction. Neurourol Urodynam 4:317–328

    Article  Google Scholar 

  5. Anonymous (1983) Phenoxybenzamine for symptoms of bladder neck obstruction. Drugs Ther Bull 21:15–16

    Google Scholar 

  6. Ball AJ, Feneley RCL, Abrams PH (1981) The natural history of untreated prostatism. Br J Urol 53:613–616

    Article  PubMed  CAS  Google Scholar 

  7. Bartsch G, Muller HR, Oberholzer M, Rohr HP (1979) Light microscopic stereological analysis of the normal human prostate and of benign prostatic hyperplasia. J Urol 122:487

    PubMed  CAS  Google Scholar 

  8. Birkoff JD, Weiderhorn AR, Hamilington ML, Zinssen HH (1976) Natural history of benign prostatic and acute urinary retention. Urology 7:48–52

    Article  Google Scholar 

  9. Boreham PF, Braithwaite P, Milewski P, Pearson H (1977) Alpha-adrenergic blockers in prostatism. Br J Surg 4:756–757

    Article  Google Scholar 

  10. Brooks ME, Sidi AA, Hanani Y, Braf ZF (1983) Ineffectiveness of phenoxybenzamine in treatment of benign prostatic hypertrophy. A controlled study. Urology 21:474–478

    Article  PubMed  CAS  Google Scholar 

  11. Cabot AT (1896) The question of castration for enlarged prostate. Ann Surg 24:265–309

    Article  PubMed  CAS  Google Scholar 

  12. Caine M, Perlberg S, Gordon R (1975) The treatment of benign prostatic hypertrophy with flutamide (SCH 13521): a placebo-controlled study. J Urol 114:564

    PubMed  CAS  Google Scholar 

  13. Caine M, Pfau A, Perlberg S (1976) The use of alpha adrenoceptor blockers in benign prostatic obstruction. Br J Urol 48:255–263

    PubMed  CAS  Google Scholar 

  14. Caine M, Perlberg S, Meretyk S (1978) A placebo-controlled double-blind study of the effect of phenoxybenzamine in benign prostatic obstruction. Br J Urol 50:551–554

    Article  PubMed  CAS  Google Scholar 

  15. Cambridge D, Davey MJ, Massingham R (1977) Prazosin, a selective antagonist of post-synaptic alpha-adrenoceptors. Br J Pharmacol 59:514P–515P

    PubMed  CAS  Google Scholar 

  16. Castro JE, Griffiths HJL, Edwards DE (1971) A double-blind, controlled, clinical trial of spirinolactone for benign prostatic hyperplasia. Br J Surg 58:485–489

    Article  PubMed  CAS  Google Scholar 

  17. Chapple CR, Aubry ML, James S et al. (1989) Characterisation of human prostatic adrenoceptors using pharmacology receptor binding and localisation. Br J Urol 63:487–496

    Article  PubMed  CAS  Google Scholar 

  18. Chapple CR, Christmas TJ, Milroy EJG (1990) A twelve-week placebo-controlled study of prazosin in the treatment of prostatic obstruction. Urol Int 45 [Suppl l]:47–55

    Article  PubMed  Google Scholar 

  19. Chapple CR, Carter P, Christmas TJ, Noble JG, Miller P, Kirby RS, Abrams P, Milroy EJG (1991) A three month double-blind placebo controlled study of doxazosin as treatment for benign prostatic bladder outflow obstruction. Neurourol Urodynam 10:308–309

    Google Scholar 

  20. Chapple CR, Burt R, Marshall I (1991) α1 Adrenoceptor subtypes in the human prostate and inferior epigastric artery. Neurourol Urodynam 10:306–308

    Google Scholar 

  21. Chapple CR, Stott M, Abrams PH, Christmas TJ, Milroy EJG (1992) A twelve-week placebo-controlled study of prazosin in the treatment of prostatic obstruction due to benign prostatic hyperplasia. Br J Urol (in press)

    Google Scholar 

  22. Chisholm GD (1989) Benign prostatic hyperplasia: the best treatment. Br Med J 299:215–216

    Article  CAS  Google Scholar 

  23. Chow W, Hahn D, Sandhu D, Slaney P, Henshaw R, Das G, Wells P (1990) Multicentre controlled trial of indoramin in the symptomatic relief of benign prostatic hypertrophy. Br J Urol 65:36–38

    Article  PubMed  CAS  Google Scholar 

  24. Clarke R (1937) The prostate and the endocrines: a control series. Br J Urol 9:254–271

    Article  Google Scholar 

  25. Craigen AA, Hickling JB, Saunders CRG, Carpenter RG (1969) Natural history of prostatic obstruction. J R Coll Gen Pract 18:226–232

    PubMed  CAS  Google Scholar 

  26. Damrau F (1962) Benign prostatic hypertrophy: amino acid therapy for symptomatic relief. J Am Geriatr Soc 10:426–430

    PubMed  CAS  Google Scholar 

  27. Donker PJ, Ivanovici F, Noach EL (1972) Analyses of the urethral pressure profile by means of electromyography and the administration of drugs. Br J Urol 44:180–193

    Article  PubMed  CAS  Google Scholar 

  28. Donkervoort T, Zinner NR, Sterling AM, Donker PJ, Van Ness J, Ritter RC (1975) Megesterol acetate in treatment of benign prostatic hyperplasia. Urology 6:580

    Article  PubMed  CAS  Google Scholar 

  29. Fabricius PG, Weizert P, Dunzendorfer U, MacHannaford J, Maurath C (1990) Efficacy of once-a-day terazosin in benign prostatic hyperplasia: a randomised placebo controlled clinical trial. Prostate Suppl 3:85–93

    Article  PubMed  CAS  Google Scholar 

  30. Furuya S, Kumamoto Y, Yokoyama E, Tsukamoto T, Izumi T, Abiko Y (1982) Alpha-adrenergic activity and urethral pressure profilometry in prostatic zone in benign prostatic hypertrophy. J Urol 128:836–839

    PubMed  CAS  Google Scholar 

  31. Garraway WM, Collins GN, Lee RJ (1991) High prevalence of benign prostatic hypertrophy in the community. Lancet 338:469–471

    Article  PubMed  CAS  Google Scholar 

  32. Geller J, Bora R, Roberts T et al. (1965) Treatment of benign prostatic hypertrophy with hydroxyprogesterone caproate: effect on clinical symptoms, morphology and of endocrine function. JAMA 193:121

    Article  PubMed  CAS  Google Scholar 

  33. Geller J, Nelson CG, Albert JD, Pratl C (1979) Effect of megesterol acetate on uroflow rates in patients with benign prostatic hypertrophy: double-blind study. Urology 14:467

    Article  PubMed  CAS  Google Scholar 

  34. Geller (1989) Pathogenesis and medical treatment of benign prostatic hyperplasia. Prostate Suppl 2:95–104

    Article  Google Scholar 

  35. Gerstenberg T, Blaabjerg J, Nielsen ML, Clausen S (1980) Phenoxybenzamine reduces bladder outlet obstruction in benign prostatic hyperplasia. A urodynamic investigation. Invest Urol 18:29–31

    PubMed  CAS  Google Scholar 

  36. Glynn RJ, Campion EW, Bouchard GR, Silbert JE (1985) The development of benign prostatic hyperplasia among volunteers in the normative aging study. Am J Epidemiol 121:78–82

    PubMed  CAS  Google Scholar 

  37. Gup D, Shapiro E, Baumann M et al. (1990) Autonomic receptors in human prostate adenomas. J Urol 143:179–185

    PubMed  CAS  Google Scholar 

  38. Hedlund H, Andersson KE, Ek A (1983) Effects of prazosin in patients with benign prostatic obstruction. J Urol 130:275–278

    PubMed  CAS  Google Scholar 

  39. Hedlund H, Andersson KE (1988) Effects of prazosin and carbachol in patients with benign prostatic obstruction. Scand J Urol Nephrol 22:19–22

    PubMed  CAS  Google Scholar 

  40. Hedlund H, Andersson KE, Larsson B (1985) Alpha-adrenoreceptors and muscarinic receptors in the isolated human prostate. J Urol 134:1291–1298

    PubMed  CAS  Google Scholar 

  41. Huggins C, Stevens RA (1940) The effect of castration on benign hypertrophy of the prostate in man. J Urol 43:705–714

    Google Scholar 

  42. Hunter J (1786) Observations on the glands situated between the rectum and the bladder called vesiculae seminales. In: Palmer JF (ed) Collected works, vol 4. Longman, London, p 31

    Google Scholar 

  43. Iacovou JW, Dunn M (1987) Indoramin — an effective new drug in the management of bladder outflow obstruction. Br J Urol 60:526–528

    Article  PubMed  CAS  Google Scholar 

  44. Isaacs JT (1990) Importance of the natural history of benign prostatic hyperplasia in the evaluation of pharmacologic intervention. Prostate Suppl 3:1–7

    Article  PubMed  CAS  Google Scholar 

  45. James S, Chapple CR, Phillips MI, Bumstock G (1989) Autoradiographic analysis of alpha-adrenoceptors and muscarinic cholinergic receptors in hyperplastic human prostate. J Urol 142:438–444

    PubMed  CAS  Google Scholar 

  46. Jardin A, Bensadoun H, Delauche-Cavallier MC, Attali P (1991) Alfuzosin for treatment of benign prostatic hypertrophy. Lancet 337:1457–1461

    Article  PubMed  CAS  Google Scholar 

  47. Kawabe K, Niijima T (1987) Use of an α1-blocker, YM-12617, in micturition difficulty. Urol Int 42:280–284

    Article  PubMed  CAS  Google Scholar 

  48. Kawabe K, Ueno A, Takimoto Y, Aso Y, Kato H (1990) Use of an 1-blocker, YM617, in the treatment of benign prostatic hypertrophy. J Urol 144:908–912

    PubMed  CAS  Google Scholar 

  49. Kirby RS, Coppinger SWC, Corcoran MO, Chapple CR, Flannagan M, Milroy EJG (1987) Prazosin in the treatment of prostatic obstruction: a placebo-controlled study. Br J Urol 60:136–142

    Article  PubMed  CAS  Google Scholar 

  50. Learmonth JR (1931) A contribution to the neurophysiology of the urinary bladder in man. Brain 54:147–176

    Article  Google Scholar 

  51. Le Duc A, Cariou G, Baron JC et al. (1990) A multicenter, double-blind, placebo-controlled of the efficacy of prazosin in the treatment of dysuria associated with benign prostatic hypertrophy. Urol Int 45 [Suppl 1]:56–62

    Article  PubMed  Google Scholar 

  52. Lepor H (1989) Non-operative management of benign prostatic hyperplasia. J Urol 141:1283–1289

    PubMed  CAS  Google Scholar 

  53. Lepor H, Knapp-Maloney G, Sunshine H (1990) A dose titration study evaluating terazosin, a selective, once-a-day α1-blocker for the treatment of symptomatic benign prostatic hyperplasia. J Urol 144:1393–1398

    PubMed  CAS  Google Scholar 

  54. Lepor H, Knapp-Maloney G (1991) Outcome assessment of terazosin for benign prostatic hyperplasia (BPH): 18 month follow-up. J Urol 145:263A

    Google Scholar 

  55. Levine AC, Kirschenbaum A, Kaplan P, Droller MJ, Gabrilove JL (1989) Serum prostate-antigen levels in patients with benign prostatic hyperplasia treated with leuprolide. Urology 34:10

    Article  PubMed  CAS  Google Scholar 

  56. Martorana G, Giberti C, Damonte P et al. (1984) The effect of prazosin in benign prostatic hypertrophy: a placebo-controlled double-blind study. IRCS Med Sci 12:11–12

    Google Scholar 

  57. Matzkin H, Chen J, Lewysohn O, Braf Z (1991) Treatment of benign prostatic hypertrophy by a long-acting gonadotropin-releasing analogue: 1-year experience. J Urol 145:309–312

    PubMed  CAS  Google Scholar 

  58. Meiraz D, Margolin Y, Lev-Ran A, Lazebnik J (1977) Treatment of benign prostatic hyperplasia with hydroxyprogesterone-caproate: placebo-controlled study. Urology 9:144

    Article  PubMed  CAS  Google Scholar 

  59. Minneman KP (1988) α1 Adrenergic receptor sub-types, inositol phosphates and sources of cell calcium. Pharmacol Rev 40:87–119

    PubMed  CAS  Google Scholar 

  60. Moore RA (1944) Benign hypertrophy and carcinoma of the prostate: occurrence and experimental production in animals. Surgery 16:152–167

    Google Scholar 

  61. Noble JG, Chapple CR, Milroy EJG (1991) Long term selective α1 adrenoceptor blockade versus surgery in the treatment of benign prostatic hyperplasia. Neurourol Urodynam 10:296–298

    Google Scholar 

  62. Perlberg S, Caine M (1982) Adrenergic response of bladder muscle in prostatic obstruction. Urology 20:524–527

    Article  PubMed  CAS  Google Scholar 

  63. Peters CA, Walsh PC (1987) The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia. N Engl J Med 317:599

    Article  PubMed  CAS  Google Scholar 

  64. Piascik MT, Butler BT, Pruitt TA, Kusiak JW (1990) Agonist interaction with alkylation-sensitive and resistant α1 adrenoceptor sub-types. J Pharmacol Exp Ther 204:982–991

    Google Scholar 

  65. Ramsay JWA, Scott GI, Whitfield HN (1985) A double-blind controlled trial of a new α-1 blocking drug in the treatment of bladder outflow obstruction. Br J Urol 57:657–659

    Article  PubMed  CAS  Google Scholar 

  66. Rango RC, McLeod PJ, Ruedy J, Ogilvie RI (1971) Treatment of benign prostatic hypertrophy with medrogestone. Clin Pharmacol Ther 12:658–665

    Google Scholar 

  67. Roos NP, Wennberg JE, Malenka DJ et al. (1989) Mortality and re-operation after open and transurethral resection of the prostate for benign prostatic hyperplasia. N Engl J Med 320:1120–1123

    Article  PubMed  CAS  Google Scholar 

  68. Schweikert HU, Tunn UW (1987) Effects of the aromatase inhibitor testolac-tone on human benign prostatic hyperplasia. Steroids 50:191–199

    Article  PubMed  CAS  Google Scholar 

  69. Scott WW, Wade JC (1969) Medical treatment of benign prostatic hyperplasia with cyproterone acetate. J Urol 101:89

    Google Scholar 

  70. Shapiro A, Mazouz B, Caine M (1981) The α adrenergic effect of prazosin on the human prostate. Urol Res 9:17–20

    Article  PubMed  CAS  Google Scholar 

  71. Stoner E (1991) Phase 111 studies evaluating 5α-reductase inhibitor and proscar. J Urol 145:57A

    Google Scholar 

  72. Stott MA, Abrams PH (1991) Indoramin in the treatment of prostatic bladder outflow obstruction. Br J Urol 67:499–501

    Article  PubMed  CAS  Google Scholar 

  73. Straughan JL (1978) Urinary incontinence with prazosin. S Afr Med J 53:882

    PubMed  CAS  Google Scholar 

  74. Thien T, Delaere KP, Debruyne FM et al. (1978) Urinary incontinence caused by prazosin. Br Med J 1:622–623

    Article  PubMed  CAS  Google Scholar 

  75. Tunn UW, Kaivers P, Schweikert HU (1985) Conservative treatment for benign prostatic hyperplasia. In: Bruchovsky N, Chapdeleine A, Newmann F (eds) Regulation of androgen action. Bruckner, Berlin, pp 87–90

    Google Scholar 

  76. Wein AJ (1989) Prazosin in the treatment of prostatic obstruction. J Urol 141:693–694

    Google Scholar 

  77. White JW (1895) The results of double castration in hypertrophy of the prostate. Ann Surg 22:1–80

    Article  PubMed  CAS  Google Scholar 

  78. Zuckerman S (1936) The endocrine control of the prostate. Proc R Soc Med 29:1557–1568

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, The Royal Hallamshire Hospital, Glossop Road, Sheffield, S10 2JF, UK

    C. R. Chapple

Authors
  1. C. R. Chapple
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Medizinische Fakultät der RWTH Aachen, Urologische Klinik, Pauwelsstraße 30, W-5100, Aachen, Germany

    Gerhard Jakse

  2. Service d’Urologie, Centre Hospitalier Universitaire, Domaine Universitaire du Sart Tilman B 35, B-4000, Liège 1, Belgium

    Christian Bouffioux  & Jean de Leval  & 

  3. Department of Urology, Academisch Ziekenhuis Maastricht, P. Debyelaan 25, 6202 AZ, Maastricht, The Netherlands

    Rudi A. Janknegt

Rights and permissions

Reprints and permissions

Copyright information

© 1992 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Chapple, C.R. (1992). Is Pharmacotherapy for Benign Prostatic Hyperplasia an Alternative?. In: Jakse, G., Bouffioux, C., de Leval, J., Janknegt, R.A. (eds) Benign Prostatic Hyperplasia. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-77480-5_16

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-77480-5_16

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-77482-9

  • Online ISBN: 978-3-642-77480-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation